About
Approach
Programs
Patients
Investors
News & Events
Careers
Contact

PIPE-359, a novel, potent and selective M1 muscarinic receptor antagonist as a therapeutic approach for remyelination in multiple sclerosis

« Go Back

PIPE-359, a novel, potent and selective M1 muscarinic receptor antagonist as a therapeutic approach for remyelination in multiple sclerosis

Explore

About
Approach
Programs
Patients
Investors
News & Events
Careers
Contact

Contact

10578 Science Center Drive Ste. 200
San Diego, CA 92121

Direct: +1.858.333.5280

info@contineum-tx.com

Follow

Legal

About
Approach
Programs
Patients
Investors
News & Events
Careers
Contact

We are using cookies to give you the best experience on our website. To find out more about the information we collect please visit our Privacy Policy

You can find out more about which cookies we are using or switch them off in .

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

For more information about the data we collect please visit our Privacy Policy.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!